A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma

Administered by either intravenous or subcutaneous infusions, in combination with the applicable backbone treatment.

Administered subcutaneously in accordance with product labeling and local standards.

Administered orally in accordance with product labeling and local standards.

Administered intravenously or orally in accordance with product labeling and local standards.

Administered orally in accordance with product labeling and local standards.

Administered intravenously or orally in accordance with product labeling and local standards.

Administered orally in accordance with product labeling and local standards.

Administered in prophylactic doses intravenously (or equivalent) in accordance with product labeling and local standards.

Administered in prophylactic doses by mouth in accordance with product labeling and local standards.

Administered intravenously in accordance with product labeling and local standards.

Administered orally in accordance with product labeling and local standards.

Administered intravenously or orally only with the first daratumumab dose in accordance with product labeling and local standards.